These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19465238)

  • 1. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
    Martinet L; Poupot R; Fournié JJ
    Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
    Braza MS; Klein B
    Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells.
    Martinet L; Fleury-Cappellesso S; Gadelorge M; Dietrich G; Bourin P; Fournié JJ; Poupot R
    Eur J Immunol; 2009 Mar; 39(3):752-62. PubMed ID: 19197941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
    Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
    J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. gammadelta T cells: a new frontier for immunotherapy?
    Lamb LS; Lopez RD
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):161-8. PubMed ID: 15744234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing γδ T cells in anticancer immunotherapy.
    Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
    Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
    Guo BL; Liu Z; Aldrich WA; Lopez RD
    Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
    Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
    Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
    Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
    Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
    Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
    Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How tumors might withstand γδ T-cell attack.
    Capietto AH; Martinet L; Fournié JJ
    Cell Mol Life Sci; 2011 Jul; 68(14):2433-42. PubMed ID: 21547501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.
    Todaro M; D'Asaro M; Caccamo N; Iovino F; Francipane MG; Meraviglia S; Orlando V; La Mendola C; Gulotta G; Salerno A; Dieli F; Stassi G
    J Immunol; 2009 Jun; 182(11):7287-96. PubMed ID: 19454726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.